A short review of ciraparantag in perspective of the currently available anticoagulant reversal agents.
Andexanet
Anticoagulants
Antidote
Ciraparantag
Idarucizumab
Journal
Drug discovery today
ISSN: 1878-5832
Titre abrégé: Drug Discov Today
Pays: England
ID NLM: 9604391
Informations de publication
Date de publication:
10 2022
10 2022
Historique:
received:
18
07
2022
accepted:
29
07
2022
pubmed:
7
8
2022
medline:
5
10
2022
entrez:
6
8
2022
Statut:
ppublish
Résumé
Despite the improved safety-profile of direct oral anticoagulants (DOACs), bleeding complications remain an important side effect of anticoagulant treatment. Although anticoagulant-specific antidotes are available, an universal anticoagulant reversal agent in case of life-threatening bleeding or emergency surgery is not yet available. Ciraparantag, a synthetic small molecule that inactivates heparins and DOAC, is a promising new reversal agent that has been investigated in phase 2 trials. In this short review we provide an overview of the preclinical and clinical evidence of ciraparantag, and compare strengths and weaknesses of ciraparantag and the currently available anticoagulant reversal strategies.
Identifiants
pubmed: 35933085
pii: S1359-6446(22)00302-6
doi: 10.1016/j.drudis.2022.07.017
pii:
doi:
Substances chimiques
Anticoagulant Reversal Agents
0
Anticoagulants
0
Antidotes
0
Piperazines
0
Recombinant Proteins
0
Heparin
9005-49-6
Arginine
94ZLA3W45F
PER977
U2R67KV65Q
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
103332Informations de copyright
Copyright © 2022 The Author(s). Published by Elsevier Ltd.. All rights reserved.